BioSpace News Archive

Aeterna Zentaris Inc., a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, reported its financial and operating results for the quarter ended March 31, 2023.

Neuronetics, Inc. a commercial stage medical technology company with a strategic vision of transforming the lives of patients whenever and wherever they need help with the best neurohealth therapies in the world, that Keith Sullivan, President and Chief Executive Officer, and Steve Furlong, Senior Vice President, Chief Financial Officer, and Treasurer will present at the JMP Securities Life Sciences on Tuesday, May 16, 2023.

Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or “the Company”), a diversified holding company with a portfolio of royalties and other healthcare assets, today reported financial results for the first quarter ended March 31, 2023, highlighted select corporate achievements and provided an overview of its key business initiatives.

Theravance Biopharma, Inc. (“Theravance Biopharma” or the “Company”) (NASDAQ: TBPH) today announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) status to ampreloxetine for the treatment of symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA).

Imalogix, an industry leader in deep learning AI for imaging, announced that world renowned radiology leader and clinical researcher Dr. Ehsan Samei has joined the Imalogix team as its Chief Scientific Advisor.

Lucence unveiled LucenceINSIGHT™, its pioneering multi-cancer early detection blood test, at their US headquarters.

Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801)and Eli Lilly and Company (“Lilly”, NYSE: LLY), jointly announced that the National Medical Products Administration (NMPA) of China has approved the supplemental New Drug Application (sNDA) for TYVYT® (sintilimab injection).

Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the first quarter ended March 31, 2023.

Electromed, Inc., a leader in innovative airway clearance technologies, announced financial results for the three months ended March 31, 2023.

Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the first quarter of 2023 and provided an update on progress toward achieving key corporate objectives, as well as commercial, clinical and pipeline development milestones.